CTMX · CytomX Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Sean A. McCarthy President and CEO | ▼ Sell | Open Market | 1,078,922 Shares held | 3/17/2026 | View profile |
| Marcia Belvin SVP, Chief Scientific Officer | ▼ Sell | Open Market | 300,760 Shares held | 3/17/2026 | View profile |
| Christopher Ogden SVP, Finance and Accounting | ▼ Sell | Open Market | 295,324 Shares held | 6/15/2026 | View profile |
| Yu-Waye Chu Senior VP Clinical Development | ▼ Sell | Open Market | 189,446 Shares held | 3/17/2026 | View profile |
| Lloyd A. Rowland General Counsel | ▼ Sell | Open Market | 120,594 Shares held | 3/18/2025 | View profile |
| Landau Jeffrey B Chief Business Officer | ▼ Sell | Open Market | 119,056 Shares held | 8/20/2024 | View profile |
| Alejandra Carvajal Chief Legal Officer | ▲ Buy | Grant | 100,000 Shares held | 8/3/2026 | View profile |
| Peterson Amy C. EVP Prod Dev & Med Aff & CMO | ▼ Sell | Open Market | 58,433 Shares held | 3/16/2023 | View profile |
| Campoy Carlos Chief Financial Officer | ▼ Sell | Open Market | 38,224 Shares held | 3/16/2023 | View profile |
| HANNAH ALISON L. Director | ▼ Sell | Open Market | 31,898 Shares held | 7/20/2022 | View profile |
| Rachael Lester Chief Business Officer | ▲ Buy | Grant | 20,000 Shares held | 2/2/2026 | View profile |
| Jones Elaine V | ▲ Buy | Open Market | 5,142 Shares held | 3/29/2023 | View profile |
Transaction History
| Alejandra Carvajal | ▲ Buy | Grant | 100,000 | $0 | 8/3/2026 |
| Christopher Ogden | ▼ Sell | Open Market | 1,624 | $5K | 6/15/2026 |
| Yu-Waye Chu | ▼ Sell | Open Market | 21,279 | $137K | 3/17/2026 |
| Sean A. McCarthy | ▼ Sell | Open Market | 118,969 | $764K | 3/17/2026 |
| Marcia Belvin | ▼ Sell | Open Market | 31,492 | $202K | 3/17/2026 |
| Christopher Ogden | ▼ Sell | Open Market | 19,323 | $124K | 3/17/2026 |
| Christopher Ogden | ▲ Buy | Grant | 90,000 | $0 | 2/2/2026 |
| Rachael Lester | ▲ Buy | Grant | 20,000 | $0 | 2/2/2026 |
| Yu-Waye Chu | ▲ Buy | Grant | 75,000 | $0 | 2/2/2026 |
| Marcia Belvin | ▲ Buy | Grant | 60,000 | $0 | 2/2/2026 |
| Sean A. McCarthy | ▲ Buy | Grant | 210,000 | $0 | 2/2/2026 |
| Sean A. McCarthy | ▼ Sell | Open Market | 101,793 | $462K | 11/6/2025 |
| Christopher Ogden | ▼ Sell | Open Market | 10,614 | $29K | 6/16/2025 |
| Marcia Belvin | ▼ Sell | Open Market | 13,884 | $37K | 6/16/2025 |
| Sean A. McCarthy | ▼ Sell | Open Market | 55,511 | $149K | 6/16/2025 |
| Christopher Ogden | ▼ Sell | Open Market | 1,641 | $5K | 6/13/2025 |
| Christopher Ogden | ▲ Buy | Option Exercise | 37,500 | $0 | 6/13/2025 |
| Marcia Belvin | ▲ Buy | Option Exercise | 37,500 | $0 | 6/13/2025 |
| Sean A. McCarthy | ▲ Buy | Option Exercise | 150,000 | $0 | 6/13/2025 |
| Sean A. McCarthy | ▼ Sell | Open Market | 37,656 | $23K | 3/18/2025 |
| Christopher Ogden | ▼ Sell | Open Market | 8,551 | $5K | 3/18/2025 |
| Yu-Waye Chu | ▼ Sell | Open Market | 4,025 | $2K | 3/18/2025 |
| Lloyd A. Rowland | ▼ Sell | Open Market | 10,203 | $6K | 3/18/2025 |
| Marcia Belvin | ▼ Sell | Open Market | 19,512 | $12K | 3/18/2025 |
| Yu-Waye Chu | ▲ Buy | Grant | 57,500 | $0 | 2/4/2025 |
| Marcia Belvin | ▲ Buy | Grant | 30,000 | $0 | 2/4/2025 |
| Christopher Ogden | ▲ Buy | Grant | 57,500 | $0 | 2/4/2025 |
| Sean A. McCarthy | ▲ Buy | Grant | 180,000 | $0 | 2/4/2025 |
| Sean A. McCarthy | ▲ Buy | Grant | 195,000 | $0 | 2/4/2025 |
| Yu-Waye Chu | ▲ Buy | Grant | 56,000 | $0 | 2/4/2025 |
| Christopher Ogden | ▲ Buy | Grant | 44,000 | $0 | 2/4/2025 |
| Marcia Belvin | ▲ Buy | Grant | 57,500 | $0 | 2/4/2025 |
| Landau Jeffrey B | ▼ Sell | Open Market | 4,181 | $5K | 8/20/2024 |
| Marcia Belvin | ▲ Buy | Option Exercise | 11,250 | $0 | 8/20/2024 |
| Marcia Belvin | ▼ Sell | Open Market | 4,181 | $5K | 8/20/2024 |
| Sean A. McCarthy | ▲ Buy | Option Exercise | 37,500 | $0 | 8/20/2024 |
| Sean A. McCarthy | ▼ Sell | Open Market | 13,898 | $17K | 8/20/2024 |
| Lloyd A. Rowland | ▲ Buy | Option Exercise | 11,250 | $0 | 8/20/2024 |
| Christopher Ogden | ▼ Sell | Open Market | 1,984 | $2K | 8/20/2024 |
| Landau Jeffrey B | ▲ Buy | Option Exercise | 11,250 | $0 | 8/20/2024 |
| Lloyd A. Rowland | ▼ Sell | Open Market | 4,181 | $5K | 8/20/2024 |
| Christopher Ogden | ▲ Buy | Option Exercise | 6,875 | $0 | 8/20/2024 |
| Christopher Ogden | ▲ Buy | Grant | 17,500 | $0 | 6/12/2024 |
| Sean A. McCarthy | ▲ Buy | Option Exercise | 109,768 | $173K | 3/26/2024 |
| Sean A. McCarthy | ▼ Sell | Open Market | 20,223 | $42K | 3/19/2024 |
| Christopher Ogden | ▼ Sell | Open Market | 2,971 | $6K | 3/19/2024 |
| Marcia Belvin | ▼ Sell | Open Market | 12,795 | $27K | 3/19/2024 |
| Landau Jeffrey B | ▼ Sell | Open Market | 6,562 | $14K | 3/19/2024 |
| Lloyd A. Rowland | ▼ Sell | Open Market | 5,268 | $11K | 3/19/2024 |
| Sean A. McCarthy | ▲ Buy | Grant | 90,000 | $0 | 1/18/2024 |
| Lloyd A. Rowland | ▲ Buy | Grant | 25,000 | $0 | 1/18/2024 |
| Christopher Ogden | ▲ Buy | Grant | 40,000 | $0 | 1/18/2024 |
| Landau Jeffrey B | ▲ Buy | Grant | 30,000 | $0 | 1/18/2024 |
| Marcia Belvin | ▲ Buy | Grant | 26,250 | $0 | 1/18/2024 |
| Yu-Waye Chu | ▲ Buy | Grant | 26,250 | $0 | 1/18/2024 |
| Sean A. McCarthy | ▼ Sell | Open Market | 13,551 | $19K | 12/20/2023 |
| Marcia Belvin | ▼ Sell | Open Market | 4,077 | $6K | 12/20/2023 |
| Landau Jeffrey B | ▼ Sell | Open Market | 4,077 | $6K | 12/20/2023 |
| Lloyd A. Rowland | ▼ Sell | Open Market | 4,077 | $6K | 12/20/2023 |
| Christopher Ogden | ▼ Sell | Open Market | 1,990 | $3K | 12/20/2023 |
| Christopher Ogden | ▲ Buy | Option Exercise | 6,875 | $0 | 12/17/2023 |
| Sean A. McCarthy | ▲ Buy | Option Exercise | 37,500 | $0 | 12/17/2023 |
| Landau Jeffrey B | ▲ Buy | Option Exercise | 11,250 | $0 | 12/17/2023 |
| Lloyd A. Rowland | ▲ Buy | Option Exercise | 11,250 | $0 | 12/17/2023 |
| Marcia Belvin | ▲ Buy | Option Exercise | 11,250 | $0 | 12/17/2023 |
| Lloyd A. Rowland | ▼ Sell | Open Market | 5,486 | $7K | 9/22/2023 |
| Sean A. McCarthy | ▼ Sell | Open Market | 14,601 | $19K | 9/22/2023 |
| Marcia Belvin | ▼ Sell | Open Market | 4,119 | $5K | 9/22/2023 |
| Landau Jeffrey B | ▼ Sell | Open Market | 4,119 | $5K | 9/22/2023 |
| Lloyd A. Rowland | ▲ Buy | Grant | 15,000 | $0 | 9/20/2023 |
| Marcia Belvin | ▲ Buy | Grant | 11,250 | $0 | 9/20/2023 |
| Landau Jeffrey B | ▲ Buy | Grant | 11,250 | $0 | 9/20/2023 |
| Sean A. McCarthy | ▲ Buy | Grant | 40,000 | $0 | 9/20/2023 |
| Sean A. McCarthy | ▲ Buy | Option Exercise | 16,535 | $26K | 5/19/2023 |
| Jones Elaine V | ▲ Buy | Open Market | 5,000 | $8K | 3/29/2023 |
| Marcia Belvin | ▲ Buy | Grant | 60,000 | $0 | 3/22/2023 |
| Christopher Ogden | ▼ Sell | Open Market | 516 | $1K | 3/16/2023 |
| Sean A. McCarthy | ▼ Sell | Open Market | 7,121 | $13K | 3/16/2023 |
| Campoy Carlos | ▼ Sell | Open Market | 1,748 | $3K | 3/16/2023 |
| Peterson Amy C. | ▼ Sell | Open Market | 4,257 | $8K | 3/16/2023 |
| Landau Jeffrey B | ▼ Sell | Open Market | 1,477 | $3K | 3/16/2023 |
| Lloyd A. Rowland | ▼ Sell | Open Market | 2,037 | $4K | 3/16/2023 |
| Christopher Ogden | ▲ Buy | Grant | 25,000 | $0 | 2/2/2023 |
| Lloyd A. Rowland | ▲ Buy | Grant | 25,000 | $0 | 2/2/2023 |
| Landau Jeffrey B | ▲ Buy | Grant | 40,000 | $0 | 2/2/2023 |
| Sean A. McCarthy | ▲ Buy | Grant | 105,000 | $0 | 2/2/2023 |
| Landau Jeffrey B | ▼ Sell | Open Market | 4,206 | $6K | 7/20/2022 |
| Lloyd A. Rowland | ▼ Sell | Open Market | 5,602 | $8K | 7/20/2022 |
| Sean A. McCarthy | ▼ Sell | Open Market | 14,911 | $21K | 7/20/2022 |
| Peterson Amy C. | ▼ Sell | Open Market | 7,463 | $11K | 7/20/2022 |
| HANNAH ALISON L. | ▼ Sell | Open Market | 5,602 | $8K | 7/20/2022 |
| Campoy Carlos | ▼ Sell | Open Market | 3,949 | $6K | 7/20/2022 |
| Lloyd A. Rowland | ▲ Buy | Grant | 15,000 | $0 | 7/19/2022 |
| HANNAH ALISON L. | ▲ Buy | Grant | 15,000 | $0 | 7/19/2022 |
| Sean A. McCarthy | ▲ Buy | Grant | 40,000 | $0 | 7/19/2022 |
| Campoy Carlos | ▲ Buy | Grant | 15,000 | $0 | 7/19/2022 |
| Peterson Amy C. | ▲ Buy | Grant | 20,000 | $0 | 7/19/2022 |
| Landau Jeffrey B | ▲ Buy | Grant | 11,250 | $0 | 7/19/2022 |
| Sean A. McCarthy | ▲ Buy | Option Exercise | 24,189 | $23K | 5/9/2022 |
| Sean A. McCarthy | ▲ Buy | Option Exercise | 66,742 | $63K | 5/9/2022 |
| Lloyd A. Rowland | ▲ Buy | Grant | 22,500 | $0 | 2/2/2022 |
| Peterson Amy C. | ▲ Buy | Grant | 40,000 | $0 | 2/2/2022 |
| HANNAH ALISON L. | ▲ Buy | Grant | 22,500 | $0 | 2/2/2022 |
| Campoy Carlos | ▲ Buy | Grant | 22,500 | $0 | 2/2/2022 |
| Sean A. McCarthy | ▲ Buy | Grant | 75,000 | $0 | 2/2/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
CTMX to Present at September Investor Conferences
CytomX Therapeutics announced it will present at upcoming investor conferences in September, a routine corporate event where biotech firms typically discuss pipeline progress and business strategy with institutional investors and analysts. The company's shares have been trading in a notably wide range over the past year, between $1.90 and $8.21, reflecting the volatility common among smaller biotechnology companies working to advance their drug candidates through development. The September conference presentations could provide updated information on CytomX's ongoing programs and corporate priorities.
CTMX to Present at September Investor Conferences. CytomX Therapeutics announced it will present at upcoming investor conferences in September, a routine corporate event where biotech firms typically discuss pipeline progress and business strategy with institutional investors and analysts. The company's shares have been trading in a notably wide range over the past year, between $1.90 and $8.21, reflecting the volatility common among smaller biotechnology companies working to advance their drug candidates through development. The September conference presentations could provide updated information on CytomX's ongoing programs and corporate priorities.